Dr. Len's Cancer Blog

Expert perspective, insight and discussion

Dr. Len's Cancer Blog

The American Cancer Society

Heatlh Information Technology (5 posts)  RSS

Laboratory Tests And Disruption In Medical Care: A New Frontier

by Dr. Len May 29, 2015

(This blog was originally published on Medpage Today and is presented here with permission)

 

Disruptive innovation is a relatively new term that refers to dynamic changes in how we live our lives. Think of your smartphone and you have a good example of disruptive technology; one that replaces old tools. Who even takes pictures with a point and shoot camera any more, or uses a map to find their way? But the rise of disruptive technologies in medicine to me raises some difficult questions.

The recent announcement by a company called Color Genomics which will provide a 19 gene assay to help women assess their risk of breast and ovarian cancer could be called a disruptive innovation. For $249, a woman can have this panel of tests done at her request so long as she has a health professional order it.

And if she doesn't have a health professional readily available, the company will be glad to provide one.

Oh, and by the way: they don't accept insurance. They reason: the company says the cost is so low that insurance companies shouldn't come between women and the test. And if you want genetic counseling, they will provide that too but only after the test is done -- which clearly contravenes the recommendations of a number of professional and voluntary health organizations.

Another example of disruption in the laboratory world is the anticipated onslaught of direct consumer availability of laboratory studies based on minimal amounts of blood, possibly at a pharmacy near you. It is not clear for now whether a health professional will be an intermediary, but the end goal is pretty clear that patients will have the opportunity to order their own labs when they want to get them. More...

Is It Time For Precision/Personalized Medicine?

by Dr. Len January 30, 2015

This blog was originally published on the Medpage Today website on January 22, 2015. It is reposted here with permission.

++++++++++++

Are we prepared for the genomics revolution?

The President's proposed Precision Medicine Initiative as mentioned in his recent State of the Union address suggests it's probably time to get ready for some changes in our daily routines as health professionals.

I'm not talking about the incredible information that has already been produced by researchers examining the human genome. Nor am I referring to the work that is going on in major cancer centers and elsewhere exploring how to better match patients with genomic analyses of their cancers, for example.

And I am not talking about the advances in targeted therapies associated with diagnostic tests that can help guide the treatment of patients with a variety of cancers including but not limited to lung and breast cancers as examples.

No, I am asking whether we are prepared to usher in the new era of medical practice where genomic analyses in one form or another will be a part of our everyday medical practice. It's not just about cancer, my friends. It will be coming to a primary care practice near you probably sooner than you realize -- but it is coming. More...

Social Media And Cancer Awareness: Are We Smart Enough To Take Advantage Of The Opportunity?

by Dr. Len June 17, 2014

This past week I had the privilege of participating in a meeting hosted by the President's Cancer Panel on the role of social media in improving cancer control and treatment. The goal was to give advice to the Panel on a planned series of meetings they will be convening to discuss the topic. It was the range and quality of the discussion that day that left me thinking about the broader topic of social media and how it could help improve cancer control going forward. More...

ASCO 2014 Is A Wrap: If Immunotherapy Is The Queen Of The Ball, Then Panomics Holds The Keys To The Kingdom

by Dr. Len June 04, 2014

As in years past, the trip home from the Annual Meeting of the American Society of Clinical Oncology in Chicago gives me a moment to reflect on what I have heard and hopefully learned over the past five days.

This meeting is a whirlwind of activity and information, far too much for any one person to absorb and process. You can be focused on one topic, you can be general, and you can hear new cutting edge research or be educated on topics of general interest in cancer. You can go to the exhibit hall and be overwhelmed by the booths and displays (I tend not to go there, but obviously many others do). I suspect you get the idea.

Ultimately for me it is the take away messages about trends in cancer research and cancer care that matter the most personally. And this year the trends appear to be somewhat similar to past years, with perhaps some new wrinkles. What is undeniable is that if immunotherapy is the queen at the ball, then "panomics" (I really like that word) holds the keys to the kingdom. More...

From The ASCO Meeting In Chicago: A Focus On Cost, Value, And Financial Toxicity Of Cancer Care

by Dr. Len May 31, 2014

At the annual meeting of the American Society of Clinical Oncology (ASCO) here in Chicago, something vitally important is happening: there is an increasing recognition of something no one really wanted to talk about in polite company until now. It is the fact that the costs of many of the new treatments being developed are extraordinary.

The headlines about cost and value of cancer care greeted me when I walked into the McCormick Center in Chicago for the opening sessions of the meeting. This is the leading cancer meeting in the world, and what happens here makes news worldwide, significantly impacting the lives of patients with cancer wherever they may be.

Now there is an increasing recognition of the elephant in the room: the costs of these new treatments are extraordinary. No matter how one chooses to slice and dice the arguments, these drugs are expensive with costs per month of $8000 and upwards getting a lot of attention and increasing concerns, especially at this meeting. More...

About Dr. Len

Dr. Len

J. Leonard Lichtenfeld, MD, MACP - Dr. Lichtenfeld is Deputy Chief Medical Officer for the national office of the American Cancer Society.

MORE »